{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:25:25Z","timestamp":1791170725991,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.expneurol.2010.11.013","type":"journal-article","created":{"date-parts":[[2010,11,25]],"date-time":"2010-11-25T09:21:50Z","timestamp":1290676910000},"page":"1-4","source":"Crossref","is-referenced-by-count":10,"title":["Statins \u2014 increasing or reducing the risk of Parkinson's disease?"],"prefix":"10.1016","volume":"228","author":[{"given":"Amalia M.","family":"Dolga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Culmsee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lonneke","family":"de Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaroslav","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang H.","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.M.","family":"Luiten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich L.M.","family":"Eisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2010.11.013_bb0005","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/j.1471-4159.2008.05254.x","article-title":"Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease","volume":"105","author":"Bar-On","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0010","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00002018-200831050-00004","article-title":"Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK","volume":"31","author":"Becker","year":"2008","journal-title":"Drug Saf."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1517\/14740330902859956","article-title":"Statins and the risk of Parkinson disease: an update on the controversy","volume":"8","author":"Becker","year":"2009","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0020","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1021\/ar0500766","article-title":"Small molecule oxidation products trigger disease-associated protein misfolding","volume":"39","author":"Bieschke","year":"2006","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0025","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nchembio782","article-title":"Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrillization","volume":"2","author":"Bosco","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0030","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/aje\/kwj283","article-title":"Serum cholesterol levels and the risk of Parkinson's disease","volume":"164","author":"de Lau","year":"2006","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0035","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/mds.21582","article-title":"Serum cholesterol, use of lipid-lowering drugs, and risk of Parkinson disease","volume":"22","author":"de Lau","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/JAD-2009-1052","article-title":"Pretreatment with lovastatin prevents N-methyl-D-aspartate-induced neurodegeneration in the magnocellular nucleus basalis and behavioral dysfunction","volume":"17","author":"Dolga","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3233\/JAD-2008-13201","article-title":"Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways","volume":"13","author":"Dolga","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0050","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1073\/pnas.87.22.8931","article-title":"Lovastatin decreases coenzyme Q levels in humans","volume":"87","author":"Folkers","year":"1990","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1016\/j.expneurol.2010.11.013_bb0055","doi-asserted-by":"crossref","first-page":"6715","DOI":"10.1523\/JNEUROSCI.1594-04.2004","article-title":"Lipid rafts mediate the synaptic localization of alpha-synuclein","volume":"24","author":"Fortin","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0060","doi-asserted-by":"crossref","first-page":"13543","DOI":"10.1523\/JNEUROSCI.4144-09.2009","article-title":"Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease","volume":"29","author":"Ghosh","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neulet.2008.09.069","article-title":"The coenzyme Q10 status of the brain regions of Parkinson's disease patients","volume":"447","author":"Hargreaves","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0070","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1471-4159.2007.05148.x","article-title":"Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide","volume":"105","author":"Hern\u00e1ndez-Romero","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0075","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1212\/01.wnl.0000312511.62699.a8","article-title":"Total cholesterol and the risk of Parkinson disease","volume":"70","author":"Hu","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2010.11.013_bb0080","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/mds.21290","article-title":"Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease","volume":"22","author":"Huang","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0085","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/mds.22013","article-title":"Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study","volume":"23","author":"Huang","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0090","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.expneurol.2009.11.015","article-title":"Lovastatin ameliorates \u03b1-synuclein accumulation and oxidation in transgenic mouse models of \u03b1-synucleinopathies","volume":"221","author":"Koob","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0185","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.","volume":"326","author":"Law","year":"2003","journal-title":"BMJ."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0095","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1517\/14740338.5.6.759","article-title":"Drug-induced parkinsonism","volume":"5","author":"Mena","year":"2006","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0100","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/ana.410370527","article-title":"Parkmsonism unmasked by Lovastatin","volume":"37","author":"M\u00fcller","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0105","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/STROKEAHA.107.501361","article-title":"Statin therapy for stroke prevention","volume":"39","author":"Nassief","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.expneurol.2010.11.013_bb0110","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1172\/JCI119812","article-title":"Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages","volume":"100","author":"Pahan","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0115","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/mds.23102","article-title":"Statin use and Parkinson's disease in Denmark","volume":"25","author":"Ritz","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0120","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jocn.2008.01.016","article-title":"Statin use and the risk of Parkinson disease: a nested case control study","volume":"15","author":"Samii","year":"2008","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0125","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejphar.2009.03.026","article-title":"Zocor Forte (simvastatin) has a neuroprotective effect against LPS striatal dopaminergic terminals injury, whereas against MPP+does not","volume":"609","author":"Santiago","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0130","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","article-title":"Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline","volume":"59","author":"Shults","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0135","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1523\/JNEUROSCI.4720-07.2008","article-title":"The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease","volume":"28","author":"Schuster","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2004.02.083","article-title":"Simvastatin prevents 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice","volume":"1037","author":"Selley","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0180","first-page":"1","article-title":"Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death.","volume":"23","author":"Sierra","year":"2010","journal-title":"J Alzheimers Dis."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0145","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1212\/01.wnl.0000271883.45010.8a","article-title":"Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease","volume":"69","author":"Simon","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2010.11.013_bb0150","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pneurobio.2009.02.002","article-title":"Statins: mechanisms of neuroprotection","volume":"88","author":"Van der Most","year":"2009","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0155","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1212\/01.wnl.0000286942.14552.51","article-title":"Statin use and the risk of Parkinson disease","volume":"70","author":"Wahner","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2010.11.013_bb0160","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neulet.2006.09.009","article-title":"Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats","volume":"408","author":"Wang","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0165","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.brainres.2005.03.016","article-title":"Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats","volume":"1045","author":"Wang","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0170","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1741-7015-5-20","article-title":"Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease","volume":"5","author":"Wolozin","year":"2007","journal-title":"BMC Med."},{"key":"10.1016\/j.expneurol.2010.11.013_bb0175","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11011-008-9096-3","article-title":"Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice","volume":"23","author":"Yokoyama","year":"2008","journal-title":"Metab. Brain Dis."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488610004140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488610004140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T14:43:57Z","timestamp":1559832237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488610004140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0014488610004140"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2010.11.013","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}